Objectives: To investigate the epidemiology and clinical relevance of triazole resistance among patients undergoing treatment for haematological malignancies who are at risk of invasive aspergillosis (IA).
Introduction
There is an increased awareness of the presence of triazoleresistant Aspergillus fumigatus and the potential risk to patients. 1 Data from case series and single-centre retrospective studies consistently show that patients with invasive aspergillosis (IA) due to triazole-resistant A. fumigatus are at high risk of treatment failure.
2 Consequently, it is reasonable to assume that triazole resistance poses a threat to any patient who is at high risk of IA, including those undergoing treatment for haematological malignancies. Mortality associated with triazole-resistant IA has also been shown to be particularly high, especially when the antifungal drug initially chosen for therapy was inappropriate or the underlying immunodeficiency persisted. [3] [4] [5] Nevertheless, the real-life implications of triazole-resistant IA are still largely unknown. Voriconazole is still considered the drug of first choice for treating IA so it is essential that a realistic estimate be made of the local rate of triazole resistance in order to decide whether the drug is an appropriate choice. A care pathway was recently proposed to aid appropriate management based on the background frequency of triazole-resistant A. fumigatus. 6 The consensus was to consider moving away from triazole monotherapy when triazole resistance exceeded 10%. However, it was also acknowledged that determining the background rate of resistance was by no means straightforward since the rate found in the environment may not necessarily reflect the frequency of IA, nor do isolates from respiratory samples necessarily reflect infection. 7 Furthermore, the frequency of triazole resistance varies considerably between countries as well as between different patient groups. 3, 4, [8] [9] [10] [11] [12] V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Hence, we set out to determine the real-life incidence of triazole resistance and the related mortality among patients at high risk of IA as a result of treatment for haematological malignancies.
Methods

Patient cohort
We performed a single-centre retrospective observational study at the Radboud University Medical Centre among 432 patients, all of whom had been admitted between 2006 and 2012 for either intensive chemotherapy for the treatment of AML or myelodysplastic syndrome (MDS) (n " 182; 42.1%) or for an allogeneic HSCT (n " 250; 57.9%). Each medical record was reviewed for the occurrence of IA. Formal ethics committee approval was not required as this was a retrospective case review and all data were handled anonymously to protect patient privacy and confidentiality.
Screening strategy
The same diagnostic-driven approach had been used during the whole period and involved twice weekly monitoring of plasma to detect galactomannan (GM) using the Platelia TM Aspergillus Ag test (Bio-Rad, Marnes-laCoquette, France). 13 A high-resolution CT scan was ordered when GM was detected in plasma (2% 0.5 or 1% 1.0) or when fever persisted for 4 days despite broad-spectrum antibacterial therapy. Bronchoscopy with bronchoalveolar lavage (BAL) was obtained when pulmonary lesions were found that were consistent with IA or other mould diseases. Mould-active antifungal prophylaxis was not given for primary prophylaxis and voriconazole was given as first-line therapy for probable or proven IA.
Mycology
Standard mycological investigations of BAL fluid included microscopy using the optical brightener Blankophor P (Bayer, Mijdrecht, The Netherlands), fungal culture and GM detection. Sabouraud's dextrose agar and broth were used for fungal culture, using the sediment of 6 mL of BAL fluid. A colony of any mould growing on agar plates designed for bacterial cultures was sent to the mycology laboratory for identification. A. fumigatus was identified by macroscopic and microscopic colony morphology and its ability to grow at 48 C. Molecular species identification was not performed routinely because, in our experience, conventional identification including thermotolerance is highly specific for A. fumigatus sensu stricto.
Susceptibility to azoles
A. fumigatus isolates were routinely screened for the presence of triazole resistance using an agar-dilution method (VIPcheck TM , Nijmegen, The Netherlands). Briefly, spores from isolated strains were incubated in a fourwell plate, of which three wells contained agar supplemented with itraconazole, voriconazole or posaconazole and the fourth served as growth control. Growth in any of the triazole-containing wells is highly suggestive of triazole resistance and all such isolates were subjected to in vitro susceptibility testing according to the EUCAST reference method.
14 The Cyp51A gene was sequenced for every confirmed resistant isolate in order to identify any resistance mutations. 15 We divided triazole phenotypes into three categories according to EUCAST clinical breakpoints: (i) susceptible (triazole MICs of itraconazole and voriconazole 1 mg/L and posaconazole 0.25 mg/L); (ii) triazole resistant (any azole with an MIC above the aforementioned concentrations); and (iii) voriconazole resistant (isolates with a voriconazole MIC .2 mg/L, as the drug is the treatment of choice for IA).
Data collection
Data were retrieved from the clinical records and recorded in a case report form and included the underlying disease and its treatment, the degree and duration of neutropenia, radiology and microbiology reports including specimens from the lower respiratory tract and biopsies as well as the use of antifungal drugs and reason for giving them. Each case report form was completed by F. B. and F. J. S. and was reviewed by J. P. D. for accuracy. The data were then entered into a specially constructed database (Filemaker Pro 13, FileMaker, Inc., Santa Clara, CA, USA).
Each potential case was independently and blindly reviewed by two investigators (W. J. F. M. v. d. V. and J. P. D.) to allow cases of possible, probable or proven IA to be identified according to the revised definitions of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) Consensus Group. 16 Disputed cases were reviewed blindly by a third investigator (P. E. V.). All remaining discrepancies were resolved by consensus (W. J. F. M. v. d. V., J. P. D. and P. E. V.).
Classification of IA
The frequency of recovery by culture of A. fumigatus and triazole resistance phenotype was assessed for patients with (probable and proven) IA and patients without IA using the revised consensus definitions of the EORTC/ MSG. 16 The primary outcome of 180 day overall mortality (day 0 set as first day of therapy for the underlying haematological disease) for patients with and without IA was assessed as well as the impact of triazole resistance.
Statistical analysis
Statistical analysis of the relationship between voriconazole resistance and mortality was performed with a two-sided Fisher's exact test. Descriptive statistics were used to describe characteristics of the patient population.
Results
Our cohort consisted of 432 consecutive patients that were admitted to the haematology department between 2006 and 2012. An overview of the IA classification of patients and the results of Aspergillus culture is shown in Figure 1 . There were 4 (0.9%) cases of proven IA, 32 (7.4%) cases of probable IA and 34 (7.8%) cases of possible IA. The remainder (83.8%) had no evidence of IA. Overall, 687 attempts at fungal culture from lower respiratory tract samples had been made, with an overall recovery rate of A. fumigatus of 6.6% (Table 1 ) and a recovery rate of 5.8% from one or more cultures from the specimens obtained from 25 patients (Figure 1 ).
In all, 36 patients were classified as having probable or proven IA (8.3%; 95% CI 6.0%-11.4%). A. fumigatus was recovered from one or more cultures of sputum, BAL or biopsy specimens in 12 probable or proven IA cases (33.3%). Two A. fumigatus isolates from separate patients were found to be triazole resistant, which corresponds to 5.8% (1 in 17) of cases of probable or proven IA. These two isolates showed a voriconazole-susceptible phenotype. A total of 34 patients were classified as having possible IA (Figure 1) . A. fumigatus was recovered from the cultures of specimens obtained from 13 (3.3%) of 396 patients without IA and triazole resistance was documented in 3 cases, of which 2 harboured voriconazole-resistant isolates (Figure 1) .
Hence, triazole resistance was identified in 2 cases with IA and in 3 cases without the disease, resulting in a rate of 1.2% (5 of 432 patients, 95% CI 0.4%-2.8%). Only two of these isolates exhibited voriconazole resistance, which corresponds to a resistance rate of 0.5% (95% CI 0.08%-1.5%). The characteristics of patients Lestrade et al. with specimens yielding triazole-resistant A. fumigatus are shown in Table 2 . The triazole resistance frequency was 20% (5 of 25 patients, 95% CI 8.4%-39.6%) among patients from whose specimens A. fumigatus had been isolated, although only a few of them developed IA. Within the group of patients with probable or proven IA, the triazole resistance frequency was 5.6% (2 of 36 cases, 95% CI 0.6%-19.1%), but the rate was 16.7% (2 of 12 cases, 95% CI 3.5%-46.0%) when considering only cases from which A. fumigatus had been isolated. Resistance mutations of the Cyp51A gene were detected in three isolates, of which two had the TR 34 /L98H mutation. No resistance mutations were found in the other resistant isolates, indicating the presence of another, as yet uncharacterized, resistance mutation (Table 2) .
Two isolates from two patients had amphotericin MICs of 2 mg/L and were also resistant to voriconazole. Anidulafungin MICs .0.032 mg/L (the highest MIC being 0.25 mg/L) were found for 16 isolates from 15 patients. The two voriconazole-resistant isolates had anidulafungin MICs of 0.125 and 0.063 mg/L, respectively.
Mortality at 180 days was significantly higher among patients with IA compared with patients without IA (36.1% in probable or proven IA versus 17.4% in those without IA; P " 0.01). There were too few cases of IA caused by voriconazole-resistant strains to determine its impact on mortality.
Discussion
The frequency of triazole resistance in our cohort of haematology patients was low as only 1 in 200 (0.5%) of all patients had IA shown to be due to triazole-resistant A. fumigatus, with 1 in 12 patients (8.3%) having probable or proven IA. Although the mortality due to IA was higher compared with those without IA, the impact of triazole-resistant IA could not be ascertained due to the low numbers involved.
Surveillance studies in the Netherlands show triazole resistance frequencies in clinical A. fumigatus isolates varying between 9.5% and 20.3%. 11 This surveillance relies on screening of all clinical Azole-resistant Aspergillus fumigatus in haematological malignancies JAC A. fumigatus isolates, including those recovered from specimens of patients without Aspergillus disease. However, studies in the Netherlands that have assessed the resistance frequency in specific patient groups generally show higher resistance rates. One Dutch single-centre ICU study reported a triazole resistance rate of 26% among patients with IA from whom the mould was recovered from respiratory specimens. 10 Another national study reported 23 ICU patients with influenza-associated IA, with 4 resistant cases (17.4%). 17 Surveillance studies performed outside the Netherlands generally show lower triazole resistance rates. For instance, in Germany a recent multicentre surveillance study of 3067 patients with acute leukaemia reported 179 cases of IA, with only two (1.1%; 1 in 100) episodes being due to triazole-resistant A. fumigatus. 18 Not surprisingly, the authors concluded that reconsideration of the initial antifungal therapy was not warranted.
The variation between triazole resistance frequencies might reflect true variation, but may also be due to differences in methodology. Two factors appear to be very important in estimating the triazole resistance frequency: the ability to detect resistance and the denominator used.
Detection of triazole resistance has mainly relied on culture. The MIC for A. fumigatus recovered by culture can be determined to allow isolates not belonging to the WT to be recognized. One obvious problem is that cultures may actually contain both triazole-susceptible and triazole-resistant A. fumigatus colonies. 19 Patients have been reported with mixed infections, in which some lesions are believed to originate from triazole-susceptible spores, while others are believed to originate from triazole-resistant A. fumigatus. 20 Triazole resistance can thus be missed unless the resistance phenotype is assessed for multiple colonies. Experts recommend analysing up to five distinct A. fumigatus colonies whenever possible. 6 We screened isolates using the VIPcheck TM system to detect triazole-resistant colonies. This system has been shown to be very effective for this purpose since the probability of resistance is very high when colonies grow on any of the wells incorporating itraconazole, voriconazole or posaconazole. 21 Conversely, inability to grow on any of these wells is highly indicative of the absence of resistance, i.e. a WT phenotype. 21 The resistance frequency also very much depends on the recovery rate from culture. In the present study, A. fumigatus was recovered from the respiratory specimens of only 1 in 15 (6.6%) patients despite the 687 attempts made to obtain a respiratory specimen. Hence, the low recovery rate was not owing to any lack of effort.
Rather, it may simply be the result of the early detection of IA that results from the diagnostic-driven approach we adopted, which allows us to start antifungal treatment when there are early signs of IA before fungi can be recovered by culture. Whichever is the case, the low rate of recovery does mean that triazole resistance is likely to be underestimated. It could be argued that patients with triazole-resistant IA are likely to fail voriconazole therapy and that A. fumigatus will then be more likely to be recovered from specimens owing to progressive disease. However, this remains conjecture as there is no evidence to support it as yet. Non-culture-based techniques, such as commercial PCR (Aspergenius V R , Pathofinder, Maastricht, The Netherlands), have been used to diagnose triazole-resistant IA in the BAL fluid samples of 201 patients in haematology, and triazole resistance mutations were found in the BAL fluid of culture-negative patients. 22 The use of this PCR might have allowed us to obtain a more accurate estimate of the triazole-resistant IA cases in our cohort. However, one drawback is that the Aspergenius V R PCR test detects only two resistance mutations (TR 34 /L98H and TR 46 /Y121F/T289A) and in our study two of five patients with triazole-resistant A. fumigatus isolates would have been missed. Nonetheless, as most cases of triazoleresistant IA are caused by the mutations that are detected by the Aspergenius V R PCR test, this assay would have been a helpful addition to our management strategy.
The denominator is a second important factor in determining the triazole resistance frequency. When the total group at risk in our population was considered, the resistance frequency was only 1 in 200 (0.5%), with only a few patients developing IA. When only the patients with probable and proven IA are considered, the frequency was 10-fold higher, at 1 in 20 (5.6%). However, fungal cultures from the specimens of most patients failed to yield A. fumigatus so the presence of triazole resistance could not be properly determined. If we consider only the patients whose specimens yielded A. fumigatus, the resistance frequency would have increased to 1 in 5 (20%). This would exceed the 10% frequency recommended by an expert panel for moving away from triazole monotherapy. 6 However, the panel did not describe how this frequency should be determined. Consequently, it may be more appropriate to use the number of cases with IA as the denominator to decide whether the proposed threshold for triazole monotherapy is still the most appropriate choice for first-line therapy. However, the denominator then includes culture-negative patients, in whom the presence of resistance cannot be accurately assessed. Furthermore, triazole-resistant A. fumigatus might More recently, we conducted a hospital-wide study in our hospital over a 5 year period among 549 patients and found 65 cases with IA associated with A. fumigatus recovered by culture, yielding a voriconazole resistance frequency of 1 in 9 (10.8%). 25 Two-thirds of these patients were in wards other than haematology, indicating that resistance frequencies may vary between different risk groups in the hospital. Consequently, the rate of resistance would need to be determined for each of the various risk groups in order to decide the best choice of antifungal for initial therapy for them. However, given the relatively low frequency of IA in general, it will prove challenging to gain an accurate estimate. Furthermore, speciation of Aspergillus and susceptibility testing would need to be routinely done, which is not the case in every hospital.
Clearly, diagnostic and therapeutic strategies for managing invasive mould diseases should be driven by knowledge of the local epidemiology. However, establishing a reliable estimate of triazole resistance is a challenge; the frequency of resistance is generally low and the diagnosis of IA and triazole resistance is far from easy, making the classification of risk to patients difficult and laborious. Nevertheless, audits are an important way of evaluating the appropriateness of current management strategies, determining trends in resistance and the distribution of resistance mutations, and supporting the most effective use of antifungal agents. We still consider voriconazole an appropriate choice for treating IA in patients with haematological malignancies as they are intensively monitored, allowing antifungal treatment to be adjusted rapidly based on clinical and radiological findings, GM monitoring and PCR for resistance. Whether this approach will change will depend upon whether or not the frequency of IA caused by azole-resistant A. fumigatus increases in the future.
